中文簡(jiǎn)介

計(jì)劃和組織《今日藥物》是一份同行評(píng)議的期刊，在科學(xué)出版物市場(chǎng)上享有40多年的聲譽(yù)。它是關(guān)于藥物進(jìn)入國(guó)際市場(chǎng)的寶貴資料來(lái)源。其最新的專著和文章，使醫(yī)學(xué)界的最新發(fā)展，在診斷和治療跨治療領(lǐng)域。本期刊包括以下部分:通過對(duì)文獻(xiàn)和制藥公司提供的信息的嚴(yán)格審查，由領(lǐng)先專家編寫的關(guān)于最近批準(zhǔn)和推出的藥物的專著和最新評(píng)論。此外，亦會(huì)公布最新的有關(guān)資料或已上市藥物的最新資料(例如新配方、新適應(yīng)癥等)。綜述文章，重點(diǎn)介紹人類疾病診斷和治療的最新進(jìn)展，以及用于診斷疾病、監(jiān)測(cè)治療反應(yīng)、預(yù)測(cè)毒性和確定靶向治療候選藥物的生物標(biāo)志物。會(huì)議報(bào)告，會(huì)議報(bào)告提供的重點(diǎn)從世界各地的主要大會(huì)和研討會(huì)。選擇要審查的主題編輯委員會(huì)由各自領(lǐng)域的主要權(quán)威人士組成，他們被挑選出來(lái)，以確保涵蓋廣泛的治療領(lǐng)域。執(zhí)行局成員建議由其領(lǐng)域內(nèi)的當(dāng)局進(jìn)行審查，以確保全面涵蓋所有主題，并強(qiáng)調(diào)所有當(dāng)前重要的問題。提交的文章在發(fā)表前要經(jīng)過同行評(píng)審。定期出版關(guān)于最近銷售的藥品和專題討論會(huì)論文集的補(bǔ)充問題。補(bǔ)編是由領(lǐng)先的專家根據(jù)當(dāng)前的科學(xué)文獻(xiàn)和他們自己的經(jīng)驗(yàn)編寫的。p-ISSN: 1699-3993, e-ISSN: 1699-4019 (B-47252-2009)成立:1965出版:12期/年和補(bǔ)編讀者簡(jiǎn)介:醫(yī)學(xué)專家，臨床醫(yī)生，市場(chǎng)營(yíng)銷和企業(yè)戰(zhàn)略總監(jiān)，藥劑師和藥理學(xué)家

投稿網(wǎng)址：https://mc.manuscriptcentral.com/prous-thomsonreuters

英文簡(jiǎn)介

AIMS & ORGANIZATIONDrugs of Today is a peer-reviewed journal with a solid reputation of over 40 years in the scientific publications market. It is a valuable source of information on drugs introduced into the international market. Its updated monographs and articles keep the medical community abreast of the latest developments in diagnosis and treatment across therapeutic areas. This journal includes the following sections:Monographs, up-to-date reviews on recently approved and launched drugs prepared by leading specialists after a rigorous review of the literature and from information provided by pharmaceutical companies. Updates with new relevant information or on line extensions of marketed drugs (e.g., novel formulations, new indications, etc.) are also published.Review articles, highlighting the latest developments in the diagnosis and treatment of human diseases, as well as biomarkers for diagnosing diseases, monitoring treatment response, predicting toxicity and identifying candidates for targeted therapy.Meeting reports, conference reports providing highlights from key congresses and symposia around the world.SELECTION OF TOPICS TO BE REVIEWEDThe Editorial Board comprises major authorities in their field who are selected to ensure that a wide variety of therapeutic areas are covered. The Board members recommend reviews from authorities within their field to guarantee that all topics are covered comprehensively and that all issues of current importance are emphasized. Submitted articles are peer reviewed before publication.Supplementary issues devoted to recently marketed drugs and symposia proceedings are periodically published. Supplements are written by leading specialists on the basis of current scientific literature and their own experience. p-ISSN: 1699-3993, e-ISSN: 1699-4019 (B-47252-2009) Established: 1965 Published: 12 issues/year and supplements Reader profile: Medical specialists, clinicians, marketing & corporate strategy directors, pharmacists & pharmacologists